Sandoz: Growth Hormone Biosimilar Efficacy Is Same As Forerunner
This article was originally published in PharmAsia News
Sandoz Japan announced the approval of additional indications of Prader-Willi Syndrome short stature without epiphyseal line occlusion and SGA short stature for its growth hormone biosimilar Sandoz on Aug. 22, meaning the drug now has the same approved efficacy as its forerunner drug.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.